On a Tuesday morning in Kampala, the heart failure ward at Mulago National Referral Hospital is full. Beds line the walls, and patients lie propped up on pillows, their chests heaving with each labored breath. The doctors do their rounds, checking oxygen levels and listening to lungs crackling with fluid. Then comes the part that no textbook prepares them for: discharging a patient who cannot afford the medicine that keeps them alive.

The medicine in question is furosemide, a diuretic that costs a few US cents per tablet. A daily dose runs roughly US$ 0.50 to 1.00, depending on where it is bought. For many Ugandans, that is a day's wage or more. So they leave the ward with a prescription they cannot fill, and they return weeks later, their lungs filled with fluid again.

This is not a story about a rare disease. Heart failure is a growing burden across sub-Saharan Africa, driven by untreated hypertension, rheumatic heart disease, and cardiomyopathy. In Uganda, the numbers are climbing, and the health system is not equipped to manage a chronic condition that requires lifelong, daily treatment.

The ward that lets people go home to die

Mulago's heart failure unit admits patients in acute crisis. They arrive breathless, unable to lie flat, with legs swollen to twice their size. The team stabilizes them with intravenous diuretics, oxygen, and sometimes inotropes. After a few days, the fluid shifts, and the patient can breathe again. But the underlying pump is still weak, and without daily oral furosemide, the fluid will return.

Discharge planning at Mulago includes a conversation about medications. The doctor writes a prescription for furosemide, an ACE inhibitor, and sometimes a beta-blocker. Then comes the question: 'Can you afford these?' Many patients shake their heads. Some ask for a cheaper alternative. Others simply take the paper and leave, knowing they will not buy it.

The ward rounds end with empty pill bottles. Nurses collect the plastic containers left behind, some still bearing labels from previous admissions. The bottles are a silent tally of failure: patients who took their medicines until the supply ran out, then stopped.

Readmissions are the norm. A 2019 study published in the Journal of the American College of Cardiology by Ssinabulya and colleagues found that roughly 30 to 40 percent of heart failure patients at Mulago were readmitted within six months of discharge. The primary reason was not disease progression, but non-adherence to medication, driven by cost.

One patient, a 54-year-old market vendor named Grace, was admitted three times in one year. Each time, she stayed for a week, received intravenous furosemide, and went home with a prescription she could not fill. 'The medicine is expensive,' she said in Luganda, through an interpreter. 'I have to choose between eating and taking tablets.'

Why a cheap pill fails in Uganda

Furosemide is on the World Health Organization's Model List of Essential Medicines. It is off-patent, manufactured by dozens of companies, and costs pennies to produce. In Uganda, it is also on the National Essential Medicines List, which means public facilities should stock it. But the reality is patchy.

The National Medical Stores, Uganda's central procurement agency, supplies public health facilities. However, stockouts are common. A 2023 survey of public facilities in central Uganda found that furosemide was out of stock in about a third of them. When it is available, it is often free or heavily subsidized. But patients discharged from Mulago may not have a nearby health center that stocks it, or they may be told to buy it from a private pharmacy.

Out-of-pocket spending dominates Uganda's health financing. According to the World Bank, nearly 40 percent of total health expenditure in Uganda comes from households paying directly at the point of care. Health insurance covers less than 10 percent of the population, and most of that is employer-sponsored schemes for formal-sector workers. The majority of Ugandans, especially those in the informal economy, pay cash for every visit, every test, and every pill.

For a patient with heart failure, the costs add up. A monthly supply of furosemide plus an ACE inhibitor can cost US$ 3 to 5. That may not sound like much, but for a family living on less than US$ 2 a day, it is a significant chunk. And heart failure often strikes people in their productive years, when they are the breadwinners. The disease itself reduces their ability to work, creating a vicious cycle of poverty and illness.

The health system, designed for acute care and infectious disease, is ill-suited for chronic conditions. Uganda has made huge strides in HIV treatment, where antiretrovirals are provided free and adherence is monitored. But heart failure drugs are not part of that pipeline. There is no PEPFAR for cardiovascular disease.

The biology of a failing pump

Heart failure is a mechanical problem. The heart muscle weakens, often because of years of uncontrolled high blood pressure or a heart attack. As the pump loses force, blood backs up into the lungs and the rest of the body. Fluid leaks out of the vessels into the tissues, causing swelling in the legs and congestion in the lungs.

The symptoms are unmistakable: shortness of breath, especially when lying down, a persistent cough, fatigue, and swollen ankles. Patients describe it as drowning from the inside. Without treatment, the fluid accumulates until the lungs are so waterlogged that oxygen cannot reach the blood. Every breath becomes a struggle.

Diuretics like furosemide work by telling the kidneys to expel more salt and water. The excess fluid is flushed out as urine, relieving the pressure on the lungs and the heart. It is not a cure. It does not repair the damaged muscle. But it keeps the patient stable, allowing them to breathe and function.

Each missed dose is a step backward. The kidney resorbs fluid, the lungs slowly fill, and the heart works harder. The process is gradual at first, then accelerates. A patient who skips a week of diuretics may feel fine for a few days, then suddenly find themselves gasping for air. By the time they reach the hospital, they are in crisis again.

The biology is unforgiving. Heart failure is a chronic, progressive condition. Without lifelong medication, the trajectory is downward. In high-income countries, patients take their daily pills and live for years. In Kampala, many patients take them intermittently, only when they can afford them, and the disease advances with each lapse.

Counting the cost of non-adherence

The cost of non-adherence is not just measured in human suffering. It is measured in hospital beds, in staff time, and in the limited resources of a public hospital that serves millions. Each readmission costs the hospital money for medications, nursing care, and meals. At Mulago, where the budget is stretched thin, every avoidable admission is a drain.

For patients, the economic burden extends beyond the drug. Transport to the hospital, often from rural areas, can cost more than the medicine. A caregiver must take time off work to accompany the patient. In a country where most people work in the informal sector, missing a day of work means losing a day of income. The total cost of a single hospital admission can easily exceed the annual cost of daily furosemide.

Some patients sell assets to pay for treatment. A farmer might sell a goat, a trader might sell her stock. These are not hypotheticals; they are documented in studies from Uganda. A 2021 study in the Journal of Global Health reported that over 60 percent of heart failure patients in Kampala had catastrophic health expenditures, defined as spending more than 40 percent of household income on health.

Non-adherence also fuels drug resistance, though not in the way that antibiotics do. The bigger issue is that patients develop tolerance to furosemide when they take it intermittently. The body adapts, and higher doses are needed to achieve the same effect. This means that even when patients do take their medicine, it may not work as well, leading to more hospitalizations.

The irony is that furosemide is one of the cheapest drugs available. A month's supply costs less than a single day in the hospital. But the system is set up so that the patient bears the cost, and the patient is the one least able to bear it.

A pilot that puts pills in hand

In 2023, the Uganda Heart Institute, which is housed at Mulago, launched a small adherence program for heart failure patients. The program, funded by a nonprofit organization, provides a free monthly supply of furosemide and other essential drugs to enrolled patients. It also assigns a community health worker to each patient, who makes phone calls and home visits to remind them to take their pills.

The results, while preliminary, are promising. Early data show a 20 to 30 percent reduction in readmissions among enrolled patients compared to a control group. The program is small, enrolling a few hundred patients, but it demonstrates that a simple intervention, providing free drugs and basic follow-up, can make a real difference.

The program is not without challenges. The cost of the drugs is borne by a nonprofit, not the state. The community health workers, who are volunteers, receive a small stipend but no formal employment. The phone reminders depend on patients having access to a mobile phone, which most do, but not all. And the program has a waiting list, because the funding is limited.

Still, the pilot offers a glimpse of what could be done. It shows that the problem is not the drug, but the system around it. If the drugs were free and the follow-up reliable, patients would take their pills and stay out of the hospital. The question is whether the government can afford to scale it up.

The program's coordinator, Dr. Sarah Nakimuli, is cautiously optimistic. 'We know what works,' she says. 'The challenge is sustainability. We need the government to take over this model, but that requires political will and a budget line.'

What it would take to sustain the fix

Scaling up the pilot would require several systemic changes. First, heart failure drugs should be firmly on Uganda's essential medicines list, and the National Medical Stores should ensure a consistent supply. Currently, furosemide is on the list, but stockouts are common. A buffer stock and better forecasting could prevent this.

Second, pooled procurement could lower prices. Uganda, like many countries, pays a premium for drugs because it buys in small quantities. By joining regional procurement initiatives, such as the East African Community's pooled procurement scheme, Uganda could negotiate lower prices for furosemide and other cardiovascular drugs.

Third, task-shifting could ease the burden on doctors. Nurses and community health workers can be trained to manage stable heart failure patients, checking for signs of fluid overload and adjusting diuretic doses under protocol. This is already done for HIV and tuberculosis, and it could work for heart failure.

Fourth, digital tools could help track refills and flag missed doses. A simple SMS reminder system, similar to those used for antenatal care, could prompt patients to refill their prescriptions. The Uganda Heart Institute is already experimenting with this, but it needs to be scaled up.

Finally, chronic disease drugs should have a budget line in district health plans. Currently, most district budgets focus on infectious diseases, maternal health, and immunization. Cardiovascular disease, which is now a leading cause of death in Uganda, receives almost no dedicated funding.

The moral arithmetic of a daily tablet

A day's supply of furosemide costs less than a bunch of matoke, the green bananas that are a staple of Ugandan cuisine. Yet patients choose food over medicine, because the consequences of skipping a meal are immediate, while the consequences of skipping a pill are delayed and invisible.

This is the moral arithmetic of chronic disease in a poor country. The system asks patients to make a choice that no one should have to make: eat today or breathe tomorrow. And when they choose to eat, the hospital sees them again, sicker than before, and the cycle repeats.

Fixing heart failure in Kampala is not about new technology or expensive devices. It is about making a 2-cent pill reliably reach the people who need it. It is about designing a health system that treats chronic disease as a priority, not an afterthought. It is about recognizing that a daily tablet, taken faithfully, can be the difference between life and a slow drowning.

The pilot at Mulago shows that the solution is within reach. But it is a pilot, not a policy. Whether it becomes a policy depends on the government's commitment to chronic care, and on the international community's willingness to fund programs that are not as glamorous as fighting an epidemic, but are just as life-saving.

As Dr. Nakimuli puts it, 'We are not asking for a miracle. We are asking for a steady supply of a drug that costs pennies. That is not too much to ask.'

Until then, the ward at Mulago will keep discharging patients who cannot afford the daily diuretic, and those patients will keep coming back, their lungs filled with fluid, until one day they do not come back at all.

What if the cost of a pill were the only barrier between a patient and their next breath? In Kampala, that question is not hypothetical. It is asked every day, in every ward, by every patient who leaves with a prescription they cannot fill. The answer, for now, is a system that fails them repeatedly, and a pilot that offers a glimpse of what could be. The real test is whether that glimpse becomes a sustained reality, or fades into another statistic.

This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.